JANX - Janux Therapeutics Inc

JANX - Janux Therapeutics Inc

https://www.januxrx.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Harrow ( NASDAQ:HROW ) , Janux Therapeutics ( NASDAQ:JANX )

Benzinga • 2 months ago • score: 0.34

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Ladenburg Thalmann analyst Aydin Huseynov initiated coverage on KALA BIO, Inc.

JANX Stock Hits Record High on Prostate Cancer Study Data

Zacks Commentary • 9 months, 1 week ago • score: -0.03

An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst - Janux Therapeutics ( NASDAQ:JANX )

Benzinga • 9 months, 1 week ago • score: 0.06

JANX007 showed strong efficacy in metastatic castration-resistant prostate cancer, with 100% achieving PSA50 declines. The therapy demonstrated durability irrespective of prior treatments. Benzinga shares with you top insiders news On Monday, Janux Therapeutics, Inc.

Janux Therapeutics ( JANX ) Moves 6.5% Higher: Will This Strength Last?

Zacks Commentary • 1 year ago • score: 0.25

Janux Therapeutics (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Janux Therapeutics, Inc. ( JANX ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 year, 1 month ago • score: 0.13

Janux Therapeutics (JANX) delivered earnings and revenue surprises of 65.63% and 1,078.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Analyst Ratings For Janux Therapeutics

Business Insider • 1 year, 4 months ago • score: 0.07

In the preceding three months, 9 analysts have released ratings for Janux Therapeutics ( NASDAQ:JANX ) , presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.

52W High

$71.71

52W Low

$21.97

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.84

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-33.80

EV/Revenue (<3 favorable)

1064.31

P/S (TTM) (<3 favorable)

3282.58

P/B (<3 favorable)

1.46

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

6.59%

Institutions (25–75% balanced)

110.00%

Shares Outstanding

60,094,000

Float

44,967,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

439,000

Gross Profit (TTM)

-67,949,000

EPS (TTM)

-1.81

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-330.02%

ROE (TTM) (>15% strong)

-0.13%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Bearish momentum

Value

-0.0055

Previous

0.0018

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025